Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
76.46%
Operating Margin
-4.76%
Net Margin
33.37%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.32%
Income Tax Rate
-0.16%
EPS
1.0700000000
Balance Sheet Analysis
Current Ratio
0.45
Cash Ratio
0.13
Working Capital
$-1.36B
Debt to Equity
3.13
Debt to Assets
28.14%
Equity Ratio
8.99%
Cash Flow Analysis
Operating Cash Flow Ratio
33.43%
Free Cash Flow Ratio
30.97%
CapEx to Revenue
2.47%
Dividends Paid
$601.19M
Stock Buybacks
No buybacks
Total Shareholder Returns
$601.19M
Cash Position Change
-18.36%
Key Takeaways (2023 FY)
Revenue declined by 29.877929738027%, indicating potential market challenges
Detailed Growth Metrics
Core Performance
Revenue
-29.88%
Net Income
-61.08%
EPS
-65.37%
Operating Income
-102.72%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
-45.56%
Operating Cash Flow
147.31%
Free Cash Flow
167.09%
Balance Sheet Health
Assets
-12.07%
Debt
-59.38%
Book Value per Share
-11.04%
Inventory
100.00%
Shareholder Returns
Dividends per Share
-7.31%
Shares Outstanding
9.66%
Long Term Trends
3Y Revenue/Share
12.50%
5Y Revenue/Share
4.08%
3Y Dividend/Share
0.07%
5Y Dividend/Share
0.96%